Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
25. Juli 2024 06:30 ET
|
Ocugen
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering,...
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
21. Juni 2024 07:00 ET
|
Ocugen
• Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial• DSMB Determination to Proceed with High Dose Cohort Dosing MALVERN, Pa., June 21, 2024 (GLOBE NEWSWIRE) --...
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
20. Juni 2024 06:30 ET
|
Ocugen
MALVERN, Pa., June 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
31. Mai 2024 08:36 ET
|
Ocugen
Established Medium Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Recommends Continuing with High-Dose Cohort Dosing with Concurrent Phase 2 Dosing MALVERN, Pa., May 31, 2024 ...
Ocugen to Present at BIO International Convention 2024
29. Mai 2024 07:15 ET
|
Ocugen
MALVERN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
28. Mai 2024 07:02 ET
|
Ocugen
MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
20. Mai 2024 07:00 ET
|
Ocugen
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
15. Mai 2024 06:30 ET
|
Ocugen
MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Provides Business Update with First Quarter 2024 Financial Results
14. Mai 2024 08:00 ET
|
Ocugen
All three first-in-class modifier gene therapy product candidates currently in the clinic with OCU400 Phase 3 in progressOCU400 on track to meet 2026 Biologics License Application (BLA) and Market...
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
10. Mai 2024 16:05 ET
|
Ocugen
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...